Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1523 | Hydroxychloroquine/Chloroquine Wiki | 1.00 |
drug481 | Blood sampling Wiki | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
D015535 | Arthritis, Psoriatic NIH | 0.50 |
D001172 | Arthritis, Rheumatoid NIH | 0.30 |
D001168 | Arthritis NIH | 0.26 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001370 | Rheumatoid arthritis HPO | 0.32 |
HP:0001369 | Arthritis HPO | 0.27 |
Navigate: Correlations HPO
There is one clinical trial.
Hypothesis: The apelin/APJ system is involved in the protection of the lung affected by the COVID-19 by interacting with the SARS-coV-2 entry door: the Angiotensin I Converting Enzyme 2 (ACE2) and the renin-angiotensin system (ras). Elevated systemic levels of apelins and ACE2 activity are associated to less critical forms of COVID-19 and characterized by less pulmonary hyperpermeability and inflammation. Goals: Main: In COVID-19+ patients, to establish the basic knowledge of 1) apelins and related systems (ras and degradation enzymes, of which ACE2) pheno-dynamic profile in bloodstream, 2) pulmonary hyperpermeability profile by biomarker's assessment i) comparison of SARS vs. lesser COVID-19 respiratory injury, and with non COVID-19 ARDS and non ARDS acute respiratory condition. Secondary: To set up links between basic and progressive clinical data (data collection system APEL-COVID).
Description: Measurement by MS/MS of the blood apelins-13/12, -17/16, -36 each 7 days during 28 days.
Measure: Blood apelins-13/12, -17/16, -36 Time: 28 daysDescription: Measurement by ELISA of the blood angiotensin II each 7 days during 28 days.
Measure: Blood angiotensin II Time: 28 daysDescription: Measurement by ELISA of the blood CC16 each 7 days during 28 days.
Measure: Blood Clara cell protein (CC16) Time: 28 daysDescription: Measurement by ELISA of the blood IL-6 each 7 days during 28 days.
Measure: Blood interleukine-6 (IL-6) Time: 28 daysDescription: Measurement by ELISA of the blood SP-D each 7 days during 28 days.
Measure: Blood surfactant protein D (SP-D) Time: 28 daysDescription: Measurement of the apelins degradation speed in plasma each 7 days during 28 days.
Measure: Plasma apelins degradation speed measurement by UPLC Time: 28 daysDescription: Measurement of the plasma ACE2 activity each 7 days during 28 days.
Measure: Plasma ACE2 activity measurement by fluorometry Time: 28 daysDescription: Measurement of the plasma kallikrein activity each 7 days during 28 days.
Measure: Plasma kallikrein activity measurement by fluorometry Time: 28 daysDescription: Measurement of the plasma neprilysin activity each 7 days during 28 days.
Measure: Plasma neprilysin activity measurement by fluorometry Time: 28 daysDescription: Measurement of the plasma ras activity each 7 days during 28 days.
Measure: Plasma ras activity measurement by fluorometry Time: 28 daysDescription: Prognostic score (APACHEII) each day during 28 days.
Measure: APACHEII Time: 28 daysDescription: Oxygenation index each day during 28 days.
Measure: Oxygenation index Time: 28 daysDescription: Duration of the mechanical ventilation.
Measure: Mechanical ventilation Time: 28 daysDescription: Measurement of the pulmonary compliance each day during 28 days.
Measure: Pulmonary compliance (Dynamic, real-time, on ventilator device: Tidal volume / Plateau pressure - PEEP Time: 28 daysDescription: Measurement of the length of hospital stay and/or mortality in-hospital.
Measure: Length of hospital stay Time: 28 daysDescription: Prognostic score (SOFA) each day during 28 days.
Measure: SOFA Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports